BigData@Heart logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 7
Grant agreement number
116074

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
9 664 970
EFPIA in kind
9 734 000
Total Cost
19 398 970

Summary

Cardiovascular disease (CVD) is a major killer in Europe, causing 3.9 million deaths (around 45% of all deaths) annually. What’s more, a third of deaths from CVD occur in the under 75s. On the economic front, CVD costs the EU around EUR 210 billion a year, with healthcare costs accounting for just over half of this figure. Three diseases – atrial fibrillation (AF), heart failure (HF) and acute coronary syndrome (ACS) are major drivers of CVD. All three are extremely complex and characterised by large differences between patients with the same diagnosis. As a result, it is hard to predict which patients will respond best to which treatments.

The BigData@Heart project is part of IMI’s Big Data for Better Outcome (BD4BO) Programme. It brings together some of Europe’s leading experts in CVD treatment and management, as well as epidemiologists, big data scientists, doctors, industry representatives, patient representatives, and ethics and legal experts. Between them, the partners have access to many cohorts and databases in this field. With this diverse team and resources, the project will be able to develop new definitions of diseases and outcomes; informatics platforms that link, visualise and harmonise different data sources; data science techniques; and guidelines on the cross-border use of big data resources. In the long term, the project expects to have an impact on our understanding of heart disease, the discovery of new targets for treatments, and progress towards personalised treatments for CVD.

Participants Show participants on map

EFPIA companies
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Institut De Recherches Internationales Servier, Suresnes, France
  • Novartis Pharma AG, Basel, Switzerland
  • Somalogic Inc, Boulder, United States
  • Vifor (International) AG, St. Gallen, Switzerland
Universities, research organisations, public bodies, non-profit groups
  • Charite - Universitaetsmedizin Berlin, Berlin, Germany
  • European Heart Network Aisbl, Bruxelles, Netherlands
  • Fundacion Para La Investigacion Del Hospital Clinico De La Comunitat Valenciana, Fundacion Incliva, Valencia, Spain
  • Karolinska Institutet, Stockholm, Sweden
  • Societe Europeenne De Cardiologie, Biot, France
  • The University Of Birmingham, Birmingham, United Kingdom
  • Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
  • University College London, London, United Kingdom
  • University of Cambridge, Cambridge, United Kingdom
  • Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • International Consortium For Healthoutcomes Measurement Inc., Cambridge, United States
  • Stichting Mlc Foundation, Den Haag, Netherlands
  • The Hyve BV, Utrecht, Netherlands
Third parties
  • International Consortium For Healthoutcomes Measurement LTD, London, United Kingdom

CONTACT

Project coordinator
Diederick GROBBEE
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
d.e.grobbee[at]umcutrecht.nl
Project leader
Gunnar BROBERT
BAYER
gunnar.brobert[at]bayer.com